Metacrine Reports Fourth-Quarter 2021 Results : vimarsana.co

SAN DIEGO, March 30, 2022 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated...

Related Keywords

Preston Klassen , Exchange Commission , Drug Administration , Metacrine Inc , Nasdaq , Private Securities Litigation Reform Act , Annual Report , Preferred Stock , Nasdaq Mtcr , Metacrine , Nc , Bd , Inflammatory Bowel Disease , Ulcerative Colitis ,